Document is current
Any future updates will be listed below
-
Authors
Li, Yijun
Kar, Soumitra
Li, Congcong
Liu, Ming
Luan, Zijian
Yuan, Guoyue
Zhong, Xing
Mu, Yiming https://orcid.org/0000-0002-3344-3540
-
Funding
Funding for this research was provided by:
Novo Nordisk A/S
- License Information
-
More Information
Article History
Received: 25 October 2024
Accepted: 27 January 2025
First Online: 28 February 2025
Declarations
:
: Yijun Li, Congcong Li, Ming Liu, and Guoyue Yuan have no conflicts of interest to report. Soumitra Kar, Zijian Luan, and Xing Zhong are employees and shareholders of Novo Nordisk. Yiming Mu reported receiving personal fees from Boehringer Ingelheim, and honoraria and personal fees from Lilly, Novo Nordisk, and Sanofi outside of the submitted work.
: ONWARDS 3 was conducted in compliance with the principles of the Declaration of Helsinki and in accordance with International Council for Harmonisation Good Clinical Practice guidelines [, ]. Relevant documents, including the protocol and consent forms, were approved by institutional review boards or independent ethics committees. All participants provided written informed consent for participation and publication of data before trial entry and could withdraw their consent at any time.
